MEFV: A Protein with Potential as A Drug Target Or Biomarker (G4210)

Target Name: MEFV

NCBI ID: G4210

MEFV

MEFV: A Protein with Potential as A Drug Target Or Biomarker

MEFV (Mesothelin-Expressive Vascular Endothelial Factor), also known as TRIM20, is a protein that is expressed in endothelial cells of the body. It is a key regulator of vascular permeability and has been implicated in a number of diseases, including heart failure, cancer, and neurodegenerative disorders. In recent years, researchers have been interested in developing MEFV as a potential drug target or biomarker for a variety of diseases.

One of the key reasons for the interest in MEFV is its role in maintaining blood-brain barrier (BBB) integrity. The BBB is a barrier that separates the brain from the surrounding blood vessels, and allows certain substances to come into the brain while keeping others out. However, in some diseases, such as cancer and neurodegenerative disorders, the BBB becomes compromised and allows harmful substances to enter the brain. By targeting MEFV, researchers hope to be able to develop treatments that can help to repair or rebuild the BBB and protect against the entry of harmful substances.

Another potential application of MEFV is its role in cancer progression.MEFV has been shown to be upregulated in a variety of cancer types, including breast, lung, and ovarian cancer. Additionally, it has been shown to play a role in the development of cancer stem cells. By targeting MEFV with drugs, researchers hope to be able to inhibit its effects and prevent cancer from progressing.

MEFV has also been shown to be involved in a number of other processes in the body, including inflammation and fibrosis. It has been shown to play a role in the regulation of immune response, and has been implicated in the development of autoimmune diseases. Additionally, MEFV has been shown to be involved in the regulation of cell proliferation, and has been implicated in the development of cancer.

In addition to its potential as a drug target or biomarker, MEFV is also of interest to researchers as a potential therapeutic agent. By using techniques such as RNA interference or genetic modification, researchers have been able to knock down or activate MEFV in order to study its effects. This has led to a better understanding of its role in various biological processes, and has opened up the possibility of using MEFV as a therapeutic agent.

Overall, MEFV is a protein that has significant potential as a drug target or biomarker for a variety of diseases. Its role in maintaining blood-brain barrier integrity, cancer progression, and inflammation makes it an attractive target for researchers. Additionally, its potential therapeutic applications have piqued the interest of pharmaceutical companies and researchers alike, and have opened up new avenues of research in the field of drug development. As research continues to advance, it is likely that the potential of MEFV will become increasingly clear.

Protein Name: MEFV Innate Immunity Regulator, Pyrin

Functions: Involved in the regulation of innate immunity and the inflammatory response in response to IFNG/IFN-gamma (PubMed:10807793, PubMed:11468188, PubMed:17964261, PubMed:18577712, PubMed:19109554, PubMed:19584923, PubMed:16037825, PubMed:27030597, PubMed:28835462, PubMed:16785446, PubMed:17431422, PubMed:26347139). Organizes autophagic machinery by serving as a platform for the assembly of ULK1, Beclin 1/BECN1, ATG16L1, and ATG8 family members and recognizes specific autophagy targets, thus coordinating target recognition with assembly of the autophagic apparatus and initiation of autophagy (PubMed:16785446, PubMed:17431422, PubMed:26347139). Acts as an autophagy receptor for the degradation of several inflammasome components, including CASP1, NLRP1 and NLRP3, hence preventing excessive IL1B- and IL18-mediated inflammation (PubMed:16785446, PubMed:17431422, PubMed:26347139). However, it can also have a positive effect in the inflammatory pathway, acting as an innate immune sensor that triggers PYCARD/ASC specks formation, caspase-1 activation, and IL1B and IL18 production (PubMed:16037825, PubMed:27030597, PubMed:28835462). Together with AIM2, also acts as a mediator of pyroptosis, necroptosis and apoptosis (PANoptosis), an integral part of host defense against pathogens, in response to bacterial infection (By similarity). It is required for PSTPIP1-induced PYCARD/ASC oligomerization and inflammasome formation (PubMed:10807793, PubMed:11468188, PubMed:17964261, PubMed:18577712, PubMed:19109554, PubMed:19584923). Recruits PSTPIP1 to inflammasomes, and is required for PSTPIP1 oligomerization (PubMed:10807793, PubMed:11468188, PubMed:17964261, PubMed:18577712, PubMed:19109554, PubMed:19584923)

The "MEFV Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEFV comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets